Skip to main content

ESTRATIFICACION DE LOS PACIENTES CON MALFORMACIONES VASCULARES “SEVERAS” EN GRUPOS DE RIESGO: INDICADORES DE GRAVEDAD Y PROGRESION SEGUN FENOTIPO/GENOTIPO/CALIDAD DE VIDA/PROS

PI20/00102

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PARA LA INVESTIGACION Y DOCENCIA SANT JOAN DE DEU
Execution centre HOSPITAL SAN JUAN DE DIOS ESPLUGUES

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib

  • Kobialka, Piotr|||0000-0003-4765-168X
  • Sabata Perez, Helena|||0000-0003-0637-0638
  • Vilalta, Odena
  • Gouveia, Leonor|||0000-0002-3825-8571
  • Angulo-Urarte, Ana|||0000-0002-8024-814X
  • Muixí, Laia
  • Zanoncello, Jasmina
  • Muñoz-Aznar, Oscar
  • Olaciregui, Nagore G.
  • Fanlo-Escudero, Lucía|||0000-0002-8364-9520
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Lavarino, Cinzia
  • Javierre, B. M.|||0000-0002-8682-6748
  • Celis, Verónica Paola
  • Rovira, Cinzia
  • López-Fernández, Susana
  • Baselga Torres, Eulàlia|||0000-0003-1086-8439
  • Mora, J.
  • Castillo, Sandra D.|||0000-0002-7007-3155
  • Graupera, Mariona|||0000-0003-4608-4185
Low-flow vascular malformations are congenital overgrowths composed of abnormal blood vessels potentially causing pain, bleeding and obstruction of different organs. These diseases are caused by oncogenic mutations in the endothelium, which result in overactivation of the PI3K/AKT pathway. Lack of robust in vivo preclinical data has prevented the development and translation into clinical trials of specific molecular therapies for these diseases. Here, we demonstrate that the Pik3ca activating mutation in endothelial cells triggers a transcriptome rewiring that leads to enhanced cell proliferation. We describe a new reproducible preclinical in vivo model of PI3K-driven vascular malformations using the postnatal mouse retina. We show that active angiogenesis is required for the pathogenesis of vascular malformations caused by activating Pik3ca mutations. Using this model, we demonstrate that the AKT inhibitor miransertib both prevents and induces the regression of PI3K-driven vascular malformations. We confirmed the efficacy of miransertib in isolated human endothelial cells with genotypes spanning most of human low-flow vascular malformations.